| Term 
 
        | alpha-glucosidase inhibitors (AGIs) Generic/trade name     |  | Definition 
 
        | -delays intestinal absorption of glucose -DA: flatulence, diarrhea, less efficacy frequent dosing -A: safety, postprandial effect Acarbose/precose miglitol/glyset voglibose/ volix |  | 
        |  | 
        
        | Term 
 
        | Amylin analogs (injectable) Generic/trade name |  | Definition 
 
        | -delays gastric emptying, decreases postprandial glucagon release, suppresses appetite -Increased risk of hypoglycemia - DA: Gi complaints, must seperate syringe - improves long term control (A1c), weight loss Pramlintide/symlin Acetate/---- |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | -decreases hepatic glucose production, increases insulin uptake in muscles -DA: transient diarrhea, nausea, bloating, anorexia, flatulence, B-12 deficiency -A: weight control, no hypoglycemia Metformin/glucophage |  | 
        |  | 
        
        | Term 
 
        | Incretin Mimetics (injectable) |  | Definition 
 
        | -mimics glucose-dependent insulin secretion, suppresses elevated glucagon secretion, delays gastric emptying -Can cause hypoglycemia when used with sulfonylurea -DA: may decrease apsortion of orally administered drugs (i.e contraceptives) -A: better glycemic control Exenatide/byetta |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | -stimulates insulin secretion in presence of glucose, short-acting -DA: frequent dosing, expensive, hypoglycemia A: short action with less hypoglycemia at night (postprandial effect) Repaglinde/prandin nateglinide/starlix |  | 
        |  | 
        
        | Term 
 
        | Sulfonylurea 1st generation |  | Definition 
 
        | -stimulates insulin secretion -Risk of hypoglycemia, weight gain, contraindicated in renal insufficiency - A: inexpensive long history of effectiveness, usually only needed once a day Generic: acetohexamide, chlorpropamide, tolazamide Trade: dymelor, diabinese, tolinase     |  | 
        |  | 
        
        | Term 
 
        | Sulfonylurea 2nd generation |  | Definition 
 
        | -stimulates insulin secretion -Risk of hypoglycemia, weight gain, contraindicated in renal insufficiency - A: inexpensive long history of effectiveness, usually only needed once a day Generic: glipizide, glipized-GITS, Glyburide, Glimepride Trade: Glucotrol, Glucotrol XL, Diabeta, Amaryl |  | 
        |  | 
        
        | Term 
 
        | Thiazolidinediones (TZDs) |  | Definition 
 
        | -decreases insulin resistance - DA: weight gain, edema, worsened CHF, most expensive, slow onset of action A: very effective in highly insulin resistant individals, potential CV benefit, usually need only once a day Pioglitazone/Actos Rosiglitazone/ Avandia |  | 
        |  |